BidaskClub cut shares of Molecular Templates (NASDAQ:MTEM) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

MTEM has been the topic of several other research reports. ValuEngine downgraded Molecular Templates from a hold rating to a sell rating in a report on Friday, December 1st. Zacks Investment Research downgraded Molecular Templates from a hold rating to a sell rating in a report on Wednesday, November 22nd. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Molecular Templates has a consensus rating of Hold and a consensus target price of $5.20.

Molecular Templates (NASDAQ MTEM) opened at $9.37 on Wednesday. Molecular Templates has a 1-year low of $3.85 and a 1-year high of $13.25. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02.

Molecular Templates (NASDAQ:MTEM) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter. The company had revenue of $0.65 million during the quarter. sell-side analysts anticipate that Molecular Templates will post -1.32 earnings per share for the current year.

An institutional investor recently bought a new position in Molecular Templates stock. OxFORD Asset Management LLP purchased a new position in Molecular Templates Inc (NASDAQ:MTEM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 20,428 shares of the biotechnology company’s stock, valued at approximately $140,000. OxFORD Asset Management LLP owned about 0.08% of Molecular Templates at the end of the most recent quarter. Hedge funds and other institutional investors own 14.59% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Molecular Templates (MTEM) Downgraded by BidaskClub to Hold” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at

Molecular Templates Company Profile

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs).

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with's FREE daily email newsletter.